CD33-targeted Bispecific Antibodies: An Emerging Therapy for Acute Myeloid Leuke Acute myeloid leukemia (AML) is a genetically heterogeneous disease characterized by the clonal expansion of leukemic cells. Despite a better understanding of the biology of AML and the recent approval of new drugs for AML, the 5-year overall survival Published 2 Years Ago by Candy Swift